Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: Population based cohort study Academic Article uri icon

Overview

MeSH Major

  • Early Detection of Cancer
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • The ratio of benefits to harms of PSA screening varies noticeably with blood PSA levels at age 60. For men with a PSA level <1 ng/mL at age 60, no further screening is recommended. Continuing to screen men with PSA levels >2 ng/mL at age 60 is beneficial, with the number needed to screen and treat being extremely favourable. Screening men with a PSA level of 1-2 ng/mL is an individual decision to be based on a discussion between patient and doctor.

publication date

  • March 28, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3968958

Digital Object Identifier (DOI)

  • 10.1136/bmj.g2296

PubMed ID

  • 24682399

Additional Document Info

start page

  • g2296

volume

  • 348